Lobbyist Melissa A. Schulman Joins GPhA Government Affairs

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Lobbyist Melissa A. Schulman Joins GPhA Government Affairs

Melissa A. Schulman, formerly the senior Democratic lobbyist at Bockorny Group, joined General Pharmaceutical Association as the company's senior vice president of government affairs. Schulman is a prominent lobbyist with deep relationships across Capitol Hill, according to GPhA, and has been ranked by several publications as one of the most influential voices in Washington. "[Schulman] brings a well-earned reputation for ensuring that her client's voice is heard," said Ralph G. Neas, GPhA CEO. "In addition, Melissa's combination of 15 years of private sector experience and 14 years working in Congress make her a perfect choice to lead our Association's advocacy efforts." Release

Melissa Schulman--General Pharmaceutical Association
Schulman will serve as VP of government affairs.

 

Ed Mascioli--Affinium Pharmaceuticals
Mascioli, an ex-Pfizer executive, will serve as CEO.

Biotech

> Affinium Pharmaceuticals appointed Ed Mascioli to be the company's new CEO. Mascioli was previously a senior executive at Pfizer ($PFE). Release

> Cardiome Pharma ($CRME) has made some changes to its senior management team. Dr. William Hunter, previously interim CEO and director, has been appointed full-time president and CEO; Karim Lalji has been promoted from senior vice president of commercial affairs to chief commercial officer; and Sheila Grant is stepping into the role of chief operating officer. Grant was previously Cardiome's VP of product development. Release

> David Novack left Novartis ($NVS) for a position at Dynavax Technologies ($DVAX) as the company's vice president of operations and quality. Story

Deborah Hartman has joined Avaxia Biologics as vice president of research. Hartman previously served as vice president of projects in innovative medicines, vice president of respiratory and inflammation research UK and vice president of Lead Generation DECS. Release

Pfizer's ($PFE) former president of R&D, John LaMattina, has been hired on as strategic adviser at Ziarco. Release

Ivan Cohen-Tanugi is joining Paris, France-based Eyevensys as CEO. Cohen-Tanugi previously served as vice president and general manager of the biologics and specialty unit at Teva Pharmaceutical Industries ($TEVA) in the U.S. Release

> Mologen AG appointed Alfredo Zurlo as the company's chief medical officer and a member of the executive board. Release

> Definiens AG created an advisory board, which includes Ron A. Andrews, Uwe Bicker, Manfred Dietel, Eric F. Glassy and Gerd Binnig. Release

Peter Willinger stepped down as the chief financial officer at Sygnis Pharma ($LIOK). Pilar de la Huerta will now serve as both CEO and CFO. Release

> The Cancer Treatment Center of America named John Conway its chief business development officer. Release

VolitionRX brought on Jason Terrell to head the company's U.S. operations. Release

Pharma

> LEO Pharma has brought on Mike Williams as head of the company's dermatology division. Williams has previously worked at pharma giants Roche ($RHHBY), AstraZeneca ($AZN), Pfizer ($PFE) and Schering-Plough. The company also appointed Barbara Reilly as head of the thrombosis division. Reilly was previously country manager for LEO Pharma's Irish affiliate. Item

Sagent Pharmaceuticals ($SGNT) has appointed James M. Hussey as its new president. He most recently held positions with NanoInk, where he served as CEO, and Ovation Pharmaceuticals, where he was vice president of strategic planning. Release

Hong Zhao has joined SciClone Pharmaceuticals as CEO of China operations. Zhao joined SciClone from Simcere Pharmaceutical Group, where he was executive vice president. Release

Medical Devices

David Comeau has stepped down as president and CEO of Albright Technologies. He will be replaced by Bob Waitt, vice president of business development. Release

Carsten Browall has been elected as the new chairman of Vitrolife AB's board of directors. Release

CRO

Jay Dixon has been appointed senior vice president of global quality and compliance at Pharmaceutical Product Development. Release

Stuart McGuire has been promoted to vice president of global business development, and Jim Szymeczek has been promoted vice president of global information technology and systems, at Chiltern International. McGuire has been with Chiltern for more than 12 years and has led the global business development team since 2009. Szymeczek joined Chiltern in 2006. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.